Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 2
1918 2
1954 1
1961 8
1962 7
1963 5
1964 10
1965 7
1966 10
1967 14
1968 10
1969 11
1970 11
1971 14
1972 4
1973 9
1974 12
1975 20
1976 16
1977 19
1978 14
1979 12
1980 15
1981 21
1982 23
1983 33
1984 20
1985 22
1986 39
1987 43
1988 52
1989 55
1990 48
1991 44
1992 40
1993 55
1994 43
1995 54
1996 60
1997 62
1998 61
1999 68
2000 62
2001 63
2002 75
2003 71
2004 105
2005 77
2006 90
2007 83
2008 77
2009 108
2010 113
2011 116
2012 111
2013 80
2014 107
2015 121
2016 133
2017 142
2018 151
2019 140
2020 189
2021 211
2022 168
2023 167
2024 206
2025 256
2026 168

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,060 results

Results by year

Filters applied: . Clear all
Page 1
Microbiota-driven antitumour immunity mediated by dendritic cell migration.
Lin NY, Fukuoka S, Koyama S, Motooka D, Tourlousse DM, Shigeno Y, Matsumoto Y, Yamano H, Murotomi K, Tamaki H, Irie T, Sugiyama E, Kumagai S, Itahashi K, Tanegashima T, Fujimaki K, Ito S, Shindo M, Tsuji T, Wake H, Watanabe K, Maeda Y, Enokida T, Tahara M, Yamashita R, Fujisawa T, Nomura M, Kawazoe A, Goto K, Doi T, Shitara K, Mano H, Sekiguchi Y, Nakamura S, Benno Y, Nishikawa H. Lin NY, et al. Among authors: goto k. Nature. 2025 Aug;644(8078):1058-1068. doi: 10.1038/s41586-025-09249-8. Epub 2025 Jul 14. Nature. 2025. PMID: 40659786 Free PMC article.
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. Le X, et al. Among authors: goto k. N Engl J Med. 2025 Nov 6;393(18):1819-1832. doi: 10.1056/NEJMoa2511065. Epub 2025 Oct 17. N Engl J Med. 2025. PMID: 41104928 Clinical Trial.
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Schram AM, et al. Among authors: goto k. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. N Engl J Med. 2025. PMID: 39908431 Free PMC article. Clinical Trial.
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Besse B, et al. Among authors: goto k. J Thorac Oncol. 2025 May;20(5):651-664. doi: 10.1016/j.jtho.2024.12.029. Epub 2025 Jan 2. J Thorac Oncol. 2025. PMID: 39755170 Free article. Clinical Trial.
Wnt/β-Catenin-Activated Nonpilomatrical Carcinoma of the Skin: A Case Series.
Kervarrec T, Cheok Lei K, Sohier P, Macagno N, Jullie ML, Frouin E, Goto K, Taniguchi K, Hamard A, Taillandier A, Tallet A, Bonenfant C, Sahin Y, Barry F, Taibjee S, Cokelaere K, Houben R, Schrama D, Nardin C, Aubin F, Doucet L, Pissaloux D, Tirode F, Fouchardière A, Balme B, Laurent-Roussel S, Becker JC, von Deimling A, Samimi M, Cribier B, Battistella M, Calonje E, Guyétan S. Kervarrec T, et al. Among authors: goto k. Mod Pathol. 2024 Nov;37(11):100586. doi: 10.1016/j.modpat.2024.100586. Epub 2024 Jul 31. Mod Pathol. 2024. PMID: 39094735 Free article.
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H. Siegel F, et al. Among authors: goto k. Cancer Discov. 2026 Jan 12;16(1):81-94. doi: 10.1158/2159-8290.CD-25-0605. Cancer Discov. 2026. PMID: 41090369 Free PMC article.
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Tomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, Besse B, Spira AI, Neal JW, Goto K, Baik CS, Marmarelis ME, Ichihara E, Zhang Y, Lee JS, Lee SH, Yang JC, Michels S, Anastasiou Z, Curtin JC, Lyu X, Mahoney J, Demirdjian L, Meyer CS, Zhang Y, Leconte I, Lorenzini P, Knoblauch RE, Trani L, Baig M, Bauml JM, Cho BC; CHRYSALIS-2 Cohort C. Tomasini P, et al. Among authors: goto k. J Clin Oncol. 2026 Jan;44(1):54-65. doi: 10.1200/JCO-24-02835. Epub 2025 Dec 1. J Clin Oncol. 2026. PMID: 41325571 Free PMC article.
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Jänne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Pereira K, Cheng FC, Taguchi A, Cheng Y, Dunton K, Ali A, Goto K. Jänne PA, et al. Among authors: goto k. J Thorac Oncol. 2025 Dec;20(12):1814-1828. doi: 10.1016/j.jtho.2025.07.129. Epub 2025 Jul 30. J Thorac Oncol. 2025. PMID: 40749900 Free article. Clinical Trial.
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Horinouchi H, et al. Among authors: goto k. Ann Oncol. 2025 May;36(5):583-591. doi: 10.1016/j.annonc.2025.01.001. Epub 2025 Jan 11. Ann Oncol. 2025. PMID: 39805351 Free article. Clinical Trial.
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Kato Y, et al. Among authors: goto k. Lung Cancer. 2024 Nov;197:107992. doi: 10.1016/j.lungcan.2024.107992. Epub 2024 Oct 13. Lung Cancer. 2024. PMID: 39423763
4,060 results